FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Clinical trial NCT03319459 · COMPLETED

Trial details

NCT number: NCT03319459
Sponsor: Fate Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2 Positive Gastric Cancer Colorectal Cancer Head and Neck Squamous Cell Carcinoma EGFR Positive Solid Tumor Advanced Solid Tumors HER2-positive Breast Cancer Hepatocellular Carcinoma Non Small Cell Lung Cancer Renal Cell Carcinoma Pancreatic Cancer Melanoma

Start date: 2018-01-18
Primary completion: 2020-05-29
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.